= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Farre-Segura

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Thursday at 9:00 (Chair: Éva Hunyadi-Gulyás)

A Newly Developed LC-MS/MS Method for the Quantitation of Glucagon in Plasma Shows the Lack of Specificity of Former RIA Methods

Jordi Farre-Segura (Presenter)
University of Liège, CHU de Liège

Presenter Bio(s): Jordi Farré obtained his degree and master-equivalent diploma in pharmacy in September 2017 by University of Barcelona. In 2016, he was firstly introduced to the clinical chemistry field in his hometown hospital’s laboratory (Althaia-Xarxa Hospitalària Universitària. Manresa, Spain) as a trainee. Later this same year he was granted with an Erasmus exchange to Liège, where he develops his research in proteomics since October 2017 as a PhD student at the Department of Clinical Chemistry, University Hospital of Liège (Belgium) under the supervision of Prof. Etienne Cavalier and Dr. Anne-Catherine Servais.
During his first stay in Belgium he contributed in the development of a new LC-MS/MS method for quantitation of Vitamin D metabolites in serum, under the supervision of Dr. Neus Fabregat and Dr. Caroline Le Goff.

Authors: Jordi Farré-Segura(1), Neus Fabregat-Cabello(1), Laurent Nyssen(1), Stéphanie Peeters(1), Caroline Le Goff(1), Etienne Cavalier(1).
(1)Department of Clinical Chemistry, University Hospital of Liège, University of Liège, Belgium.


We have developed a sensitive method for intact glucagon quantitation by LC-MS/MS based on a simple solid phase extraction. The method showed good precision, accuracy and detection limits throughout its advancement. However, our preliminary comparison with our routine radioimmunoassay (RIA) showed a significant bias. Hence, RIA provides spurious results compared to the LC-MS/MS that could suppose a change in the perspective of this peptide’s measurement.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: